Qualia NAD+ Placebo-Controlled Clinical Study Results

Qualia NAD+ Placebo-Controlled Clinical Study Results


Qualia NAD+ significantly increased NAD+ levels compared to placebo (p < 0.001) in a double-blind, placebo-controlled clinical trial. There was an average increase of 74% in NAD+ after taking Qualia NAD+ once daily for 4 weeks.*

How The Study is Designed

There were two groups in the study: one took Qualia NAD+ capsules and the other took placebo capsules. Participants were randomly assigned to be in one of the two groups.

The study was double-blinded, which means that neither the researchers conducting the study nor the participants knew who received Qualia NAD+ or placebo capsules until after the participants had completed the study protocol. 

Participants took either Qualia NAD+ or a placebo daily for 28 days. The instructions were to take two capsules every day anytime in the morning, with or without food. 

The primary study endpoint was the change in NAD+ levels, which was determined by comparing initial and final NAD+ levels using at-home finger stick blood kits.  


Qualia NAD+ Increased NAD+ Levels by an Average of 74%*The study was conducted between October 2023 and March 2024. A group of 92 adults were recruited and sent at-home finger stick blood kits to measure initial blood NAD+ levels prior to beginning supplementation.

Forty-nine participants successfully completed the initial test to obtain their baseline NAD+ measurements and were instructed to take Qualia NAD+ or placebo. Twenty-five of the 49 participants successfully completed a second NAD+ test after taking Qualia NAD+ or a placebo for 28 days. Data analysis is based on these 25 participants who had both initial and final NAD+ measurements.

The participants, who had both initial and final NAD+ measurements, ranged from 40 to 64 years old, with an average age of 49.5 years. Participants were a mix of females (N = 14) and males (N = 11).

The average increase in whole blood NAD+ levels from baseline in the group of participants taking Qualia NAD+ was 74%. This increase was statistically significant (p < 0.001) compared to the placebo group.*

†p < 0.001 comparing NAD+ level increase between Qualia NAD+ and placebo

This NAD+ increase of 74% found in this study is greater than what has been reported to occur with a similar amount of nicotinamide riboside given alone [1], indicating that the comprehensive approach taken by Qualia NAD+, which combines nicotinamide riboside with two additional NAD+ precursors and other ingredients intended to support the making of NAD+, has additive benefits and is more effective than nicotinamide riboside given alone.*

Note: The most common reasons for failing to successfully complete NAD+ measurements were: (1) failure to send in the initial or final at-home finger stick blood kits to the lab for analysis, (2) insufficient blood sample of the submitted test kit, and (3) too much time having elapsed between when the sample was collected and returned to the lab.

  1. Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9: 9772. doi:10.1038/s41598-019-46120-z

*These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure or prevent any disease. The information on this site is for educational purposes only and should not be considered medical advice. Please speak with an appropriate healthcare professional when evaluating any wellness related therapy. Please read the full medical disclaimer before taking any of the products offered on this site.